Brief: Capricor Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Hope-3 Study
03/12/2025 13:02
Dec 3 (Reuters) - Capricor Therapeutics Inc CAPR.O: CAPRICOR THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 HOPE-3 STUDY OF DERAMIOCEL IN DUCHENNE MUSCULAR DYSTROPHY CAPRICOR THERAPEUTICS INC - PHASE 3 STUDY MEETS PRIMARY AND SECONDARY ENDPOINTS CAPRICOR THERAPEUTICS INC - DERAMIOCEL MAINTAINS FAVORABLE SAFETY PROFILE CAPRICOR THERAPEUTICS INC - COMPANY TO SUBMIT RESPONSE TO COMPLETE RESPONSE LETTER Source text: ID:nGNX3NjNGk Further company coverage: CAPR.O ((Reuters.Briefs@thomsonreuters.com;))